GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bioject Medical Technologies Inc (OTCPK:BJCT) » Definitions » Preferred Stock

Bioject Medical Technologies (Bioject Medical Technologies) Preferred Stock : $9.46 Mil (As of Sep. 2011)


View and export this data going back to . Start your Free Trial

What is Bioject Medical Technologies Preferred Stock?

Preferred stock is a special equity security that has properties of both equity and debt. Bioject Medical Technologies's preferred stock for the quarter that ended in Sep. 2011 was $9.46 Mil.

The market value of preferred stock needs to be added to the market value of common stocks in the calculation of Enterprise Value. Bioject Medical Technologies's Enterprise Value for the quarter that ended in Sep. 2011 was $13.40 Mil.

In the calculation of book value, the par value of preferred stocks needs to subtracted from total equity. Bioject Medical Technologies's Book Value per Share for the quarter that ended in Sep. 2011 was $-0.44.

Dividends paid to preferred stocks need to be subtracted from net income in the calculation of Earnings per Share (Diluted). Bioject Medical Technologies's Earnings per Share (Diluted) for the three months ended in Sep. 2011 was $0.01.


Bioject Medical Technologies Preferred Stock Historical Data

The historical data trend for Bioject Medical Technologies's Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioject Medical Technologies Preferred Stock Chart

Bioject Medical Technologies Annual Data
Trend Mar01 Mar02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10
Preferred Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.80 7.20 8.03 9.28 9.38

Bioject Medical Technologies Quarterly Data
Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11
Preferred Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.36 9.38 9.41 9.43 9.46

Bioject Medical Technologies Preferred Stock Calculation

Preferred Stock is a special equity security that has properties of both equity and debt. It is generally considered a hybrid instrument. Preferred stock is senior to common stock, but is subordinate to bonds in terms of claim or rights to their share of the assets of the company.

Preferred stock has priority over common stock in the payment of dividends and any payments received when a company liquidates.

Preferred stock comes in many forms. It can be:


Convertible or Non-Convertible
Cumulative or Non-Cumulative
Voting or Non-Voting
Callable or Non-Callable
Maturity Date or No Maturity Date

A preferred stock without a maturity date is called a perpetual preferred stock. These are relatively rare. A good example of perpetual preferred stock is the many series of Public Storage (PSA) preferred shares that trade on the New York Stock Exchange.

Before investing in preferred stock, it is important to know which of the above groups the stock belongs to. Is it convertible or non-convertible? Are dividends cumulative or non-cumulative?

It is also critical that an investor knows what bonds the company has in front of the preferred stock. Bondholders get paid first. So the decision to buy a preferred stock can be similar to the decision to buy a bond. But, remember, the preferred stock of a company with bonds is junior to those bonds.

Unless a preferred stock is convertible, the upside in a preferred stock investment is more limited than in a common stock investment. If a company doubles its earnings, it is usually under no more obligation to double the dividends paid to preferred shareholders than it is to double the interest paid to its bankers and bondholders.So preferred stock is very different from common stock.


Bioject Medical Technologies  (OTCPK:BJCT) Preferred Stock Explanation

When a company needs capital but does not wish to issue debt, they may sell preferred stocks to investors.

For instance, during the financial crisis of 2008, Goldman Sachs (GS) issued a combination of preferred stock and common stock options for $5 billion of capital to Warren Buffett’s Berkshire Hathaway (BRK.A)(BRK.B). In this deal, Berkshire Hathaway paid $5 billion for 10% cumulative perpetual preferred stock and warrants to buy 43.5 million shares of Goldman Sachs at $115 a share. Goldman Sachs bought back the preferred in 2010. Guess how much money Warren Buffett made in this deal in two years? Read How Much Did Warren Buffett’s Berkshire Hathaway (BRK.B) Make on Its Goldman Sachs (GS) Preferred Stock?

1. The market value of Preferred Stocks needs to be added to the market value of common stocks in the calculation of enterprise value.

Bioject Medical Technologies's Enterprise Value for the quarter that ended in Sep. 2011 is calculated as

2. In the calculation of Book Value, the par value of Preferred Stocks needs to subtracted from total equity.

Bioject Medical Technologies's Book Value per Share for the quarter that ended in Sep. 2011 is calculated as

3. Dividends paid to Preferred Stocks need to be subtracted from net income in the calculation of earnings per share.

Bioject Medical Technologies's Earnings per Share (Diluted) (EPS) for the three months ended in Sep. 2011 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bioject Medical Technologies Preferred Stock Related Terms

Thank you for viewing the detailed overview of Bioject Medical Technologies's Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioject Medical Technologies (Bioject Medical Technologies) Business Description

Traded in Other Exchanges
N/A
Address
Bioject Medical Technologies Inc commenced operations in 1985 and is a developer and manufacturer of needle-free injection therapy systems (NFITS). The Companys long-term goal is to become supplier of needle-free injection systems to the pharmaceutical and biotechnology industries. It focused its business development efforts on new and existing licensing and supply agreements with pharmaceutical and biotechnology companies, as well as numerous research agreements that could guide to long-term agreements. The Companys pipeline of prospective new partnerships remains active. It is also actively pursuing additional opportunities both domestically and overseas as it expands its current product line. The Companys Biojector 2000 system (B2000) consists of two components: a hand-held, reusable jet injector and a sterile, single-use, disposable plastic syringe capable of delivering variable doses of medication up to 1.0 mL. Drug Reconstitution System - The needle-free drug reconstitution system allows for the transfer of diluents to reconstitute powdered medications into liquid form and withdrawal of liquid medication into a syringe without the use of a needle. Vitajet - The Vitajet is also composed of two components, a portable injector unit and a disposable syringe. It is smaller and lower in cost than other products in its needle-free offering. ZetaJet - The ZetaJet is Biojects latest advance in needle-free delivery systems. It consists of two components, the portable injector and an auto-disabling disposable syringe. The medical equipment market is very competitive. Bioject Medical Technologies has two patents: Biojector 2000 and Vitajet. The Companys products and manufacturing operations are subject to extensive government regulations, both in the U.S. and abroad. In the U.S., the Food and Drug Administration (FDA) administers the Federal Food, Drug and Cosmetic Act (FFDCA) and has adopted regulations to administer the FFDCA.
Executives
James C Gale director 152 W 57TH STREET, 19TH FLOOR, NEW YORK NY 10019
Sanders Morris Harris Inc/fa 10 percent owner, other: See General Remarks 600 TRAVIS, SUITE 5900, HOUSTON TX 77002
David S Tierney director C/O ABLE LABORATORIES, INC., 6 HOLLYWOOD COURT, CN 1013, SOUTH PLAINFIELD NJ 07080
Edward L Flynn director, 10 percent owner 211 SOMERVILLE ROAD RTE 202N, BEDMINISTER NJ 07921
Life Sciences Opportunities Fund Ii Lp 10 percent owner 152 W 57TH STREET 19TH FLOOR NEW YORK NY 10019
Lof Partners Llc other: See general remarks 152 W 57TH STREET 19TH FLOOR NEW YORK NY 10019
Life Sciences Opportunities Fund Instittutional Ii Lp 10 percent owner 152 W 57TH STREET 19TH FLOOR NEW YORK NY 10019
Randal D Chase director 28 GEORGIA COURT, RICHMOND HILL A6 L4E ON7
Brigid Makes director 20245 SW 95TH AVENUE, TUALATIN OR 97062
J Michael Redmond officer: Sr. VP Bus Dev. 10 CANTERBURY ROAD, WINDHAM NH 03087
Elan Corp Plc 10 percent owner TREASURY BUILDING, LOWER GRAND CANAL STREET, DUBLIN 2 L2 00000
Elan International Services Ltd 10 percent owner C/O TREASURY BUILDING, LOWER GRAND CANAL STREET, DUBLIN L2 2
Elan Pharmaceutical Investments Ltd 10 percent owner 102 ST JAMES COURT, FIETSS SMITH FL BERM D0 9999999999
John P Gandolfo officer: CFO 62 TERRACE ROAD, WAYNE NJ 07470
Grace K Fey director 1210 CROMWELL ROAD, HALIFAX NOVA SCOTIA A5 B3H4L2

Bioject Medical Technologies (Bioject Medical Technologies) Headlines

No Headlines